A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Panobinostat

Criteria

Inclusion criteria:

• Patients with age ≥18 years

• Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head & neck cancer

• No evidence of distant spread of the disease

Exclusion criteria:

• Patients who have severe and/or uncontrolled medical conditions

• Female patients who are pregnant or breast feeding

Other protocol-defined inclusion/exclusion criteria may apply